Telix Pharmaceuticals Ltd
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type other
SEC Category Large accelerated filer
State of Incorporation Australia
Business Address 55 FLEMINGTON ROAD, NORTH MELBOURNE, C3, 3051
Mailing Address 55 FLEMINGTON ROAD, NORTH MELBOURNE, C3, 3051
Phone 61 3 9093 3855
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 20-F Foreign company annual report | February 20, 2026 | View on SEC |
| 6-K Foreign company current report | February 19, 2026 | View on SEC |
| 6-K Foreign company current report | February 18, 2026 | View on SEC |
| 6-K Foreign company current report | February 3, 2026 | View on SEC |
| 6-K Foreign company current report | January 20, 2026 | View on SEC |
| 6-K Foreign company current report | January 12, 2026 | View on SEC |
| 6-K Foreign company current report | December 22, 2025 | View on SEC |
| 6-K Foreign company current report | December 17, 2025 | View on SEC |
| 6-K Foreign company current report | December 8, 2025 | View on SEC |
| 6-K Foreign company current report | October 14, 2025 | View on SEC |
Annual Reports
20-F February 20, 2026
- Achieved significant revenue growth, primarily from Illuccix, and moved into net profitability in 2023.
- Maintained a strong cash position, providing ample liquidity for ongoing operations and pipeline development.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.